หลักการพื้นฐานทางเภสัชจลนพลศาสตร์ และการขับยาออกจากร่างกาย

ขอ 7.4.3.10 จากแนวทางการใหยาFamciclovir (ขอมูล Clcr ผปู วย = 45 mL/min) สรปุ ดังนี้

Indication Dosing Modifications Dose in Patients

Acute herpes zoster CrCl ≥60 mL/min: Regular dosage 500 mg q12hrs
CrCl 40-59 mL/min: 500 mg q12hr
CrCl 20-39 mL/min: 500 mg once
daily
CrCl <20 mL/min: 250 mg once
daily
Hemodialysis: 250 mg after each
session
Herpes labialis CrCl ≥60 mL/min: Regular dosage 500 mg q12hrs
CrCl 40-59 mL/min: 750 mg once
CrCl 20-39 mL/min: 500 mg once
CrCl <20 mL/min: 250 mg once
Hemodialysis: 250 mg once after
dialysis
Genital herpes CrCl ≥60 mL/min: Regular dosage 500 mg q12hrs
(treatment of recurrent CrCl 40-59 mL/min: 500 mg q12hr
disease) for 1 day (2 doses total)
CrCl 20-39 mL/min: 500 mg once
CrCl <20 mL/min: 250 mg once
Hemodialysis: 250 mg once after
dialysis
Genital herpes CrCl ≥40 mL/min: Regular dosage Regular dosage =
(suppressive therapy) CrCl 20-39 mL/min: 125 mg q12hr 250 mg PO q 12hrs
CrCl <20 mL/min: 125 mg/day
Hemodialysis: 125 mg after each
session
Herpes CrCl ≥40 mL/min: Regular dosage Regular dosage =
Prevention of HSV reactivation:
(HIV-infected adults) CrCl 20-39 mL/min: 500 mg/day 500 mg PO q 12hrs
CrCl <20 mL/min: 250 mg/day Recurrent episodes: 500 mg PO
Hemodialysis: 250 mg after each 48 hrs of symptom or lesion
session onset
ที่มา https://reference.medscape.com/drug/famvir-famciclovir-34261

148

ดัชนี

คาํ หนา คํา หนา

A Edema 6
Absorption
Active transport 1F 9
AHFS drug information 6, 17 ,44, 57
Alprazolam 6, 17 ,44, 57 Folic acid
Atorvastatin 67
B 96 Flow llimited 4, 108
Biliary excretion
Biotransformation 10, 13, 69 G 40
Bowman's capsule 10, 69, 75 Gabapentin 14
C 14, 75
Capacity limited 80 Gastric emptying time
Capacity limitted binding insensitive 35
Capacity limitted binding insensitive Glomerular filtration 42
Carrier mediated transport 59
Ceftriaxone 20 Glucuronide 62
Chronopharmacokinetics 63
Chronotherapy 39 Grapefruit 59
Ciprofloxacin 40
Circadian effect H
Clearance 66 Half-life 81
Clonazepam 98
Competition 66 Henderson-Hassenbach
Conjugation 15
D 66 Hepatic artery 28
Diffusion 4 Hepatic clearance 15
Distribution 31, 33 ,111 Hepatic extraction ratio 8
Drug information handbook 21
E 102 Hepatocyte 6
Elimination
Elimination rate constant 120 Hydrostatic pressure 9
Excretion 6, 17 ,44, 57
Exporter inhibitors 31, 108, 111 I
Extraction ratio 102 Intestinal excretion 67
4, 108
20 Intracellular hydrostatic pressure

10 K
45 Ketoconazole

14 Ketoprofen
L

5 Lexicom online

5 Loading dose

98 Levothyroxine

Lisinopril

15 Liothyronine
28 Losartan
15 Lithium
8M

21 Mamary excretion

149

คาํ หนา คาํ หนา

Medscape 100 R 23, 33
Metabolism 11 Renal clearance 96
Methotrexate 82, 84,113, 118 47
Methylation 14 Rxlist drug information
Micromedex 98 7
Modified diet in renal disease (MDRD) 88 Ranitidine 81
N S 44
Naproxen 18 Sodium iodide transporter 59
Nortriptyline 13 84
O Salivary excretion 10, 13, 69-70, 72, 75
Organ clearance 21 Saturation 14
Osmotic pressure 41
Obese 7 Sinusoid 5, 17, 84
Occular permeability 118 21, 23, 50
P Sweat excretion
Passive transport 4 41, 50
Pore transport 4 Simvastatin 44, 51
Periportal Hepatocyte 61 7, 69-70, 74
Perivenous 61 Sulfation
Pharmacodynamics 1 T 8, 13-14, 64, 69
Pharmacokinetics 1 Tetracycline 64, 82, 105, 112, 119
Phase 1 metabolism 11
Phase 2 metabolism 11 Totalbody clearance 5, 10, 13, 64, 68
Portal vein 59
Protein binding 42 Tubular reabsorption 69
Permeability 6, 108
Q Tubular secretion 69
Quaternary ammonium 47, 81
Quinidine 8, 13-14, 64 Tramadol
68-69, 75, 82 V
Quinine 13, 43, 75, 81, 106 Verapamil

Valproic acid
W
Warfarin
X
Xanax
Z
zolpedem

150

ประวัติผเู ขียน

ชือ่ -นามสกุล กรณั ฑร ตั น ทิวถนอม จฬุ าลงกรณ มหาวิทยาลยั (2551)
ตําแหนง ผชู วยศาสตราจารย ดร.
สถานท่ีทํางาน คณะเภสชั ศาสตร มหาวทิ ยาลัยศลิ ปากร
การศกึ ษา ภด. (บรบิ าลทางเภสชั กรรม)

ภม. (เภสัชกรรมคลนิ ิก) มหาวทิ ยาลยั มหิดล (2545)

ภบ. มหาวิทยาลัยศลิ ปากร (2538)

Scholarship and Grant

1. The University Developing Commission (UDC) Programme 1995-1998

2. Research grant from Government Pharmaceutical Organization 1996

3. The training grant for Therapeutic Drug Mornitoring from the embassy of France 1999

4. The Faculty scholarship for participating European Society of Clinical Pharmacy conference at

Malta 2001.

5. The Faculty scholarship for PhD 2002-2003, at present

6. The CRN Schlolarship for PhD. 2003-2005

7. ISN travel grant 2005

8. Faculty research grant (2010)

9. University research grant (2011)

151

10. ISPOR Travel grant (2012)
11. NRCT research grant (2016)
12. Graduate research grant (2017)
Publications
1. Karunrat Tewthanom, Chanudom Cherachat, Chudaporn Sukkasem, Chosita Somwangprasert,
Suchima Pornbunjerd, Napa Parinyanitikul. (2018) Factor associated transtuzumab cardiotoxicity
in breast cancer: a case control study. In proceeding of Unity in Diversity and the
Standardization of Clinical Pharmacy Services: Proceedings of the 17th Asian Conference on
Clinical Pharmacy (ACCP 2017), July 28-30, 2017, Yogyakarta, Indonesia, edited by Elida Zairina,
ISBN 9781138081727.
2. Karunrat Tewthanom, Chanudom Cherachat, Chudaporn Sukkasem, Chosita Somwangprasert,
Suchima Pornbunjerd. Breast cancer therapy and cardiotoxicity of Trastuzumab in Breast
cancer patients. Veridian E-Journal, Science and Technology Silpakorn University. 2017:4(2)
March – April; 1-18.
3. Karunrat Tewthanom. Sofosbuvir: current information for hepatitis C treatment. Thai Bull Pharm
Sci. 2017; 12(1):91-107.
4. Wikawee Russameethum, Karunrat Tewthanom. Risk-benefit of high dose metformin
beyond current evidence-based pharmacotherapy. Thai Bull Pharm Sci. 2017; 12(1):55-62.
5. Tewthanom K, Jongjaroenprasert W. The pharmacokinetics of 2 doses (50 mcg and 100 mcg)
levothyroxine treatment in athyreotic patients. International Journal of Applied
Pharmaceutics. 2016:8(4); 66-68.
6. Karunrat Tewthanom, Rinsook Ongarjsakulman, Theerarat Tankhum Lithuim Serum Level
In Children; The tool for dose adjustment is needed? : Preliminary data at Yuwaprasart
Waithayopathum Child Psychiatric Hospital. 26th FAPA congress 2016. 9-13 November
2016. Bangkok, Thailand
7. Karunrat Tewthanom, Experiential Learning Model in Pharmacy Orientation Course: the
preliminary development activities for future trends of 21st Century of Pharmacy Education.
International of Pharmacy Education and Research 2016:3(3); 1-4.

152

8. Tewthanom K. “The screening of skin carotenoid concentration (SCC) in patients with
cardiovascular disease and Diabetes Mellitus: An association assessmentin single study.” In
Proceeding of 14th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology
2015. Rotterdam, Netherland, October 11-15, 2015.

9. Tewthanom K. “Cost Effectiveness Analysis among Patients with Diabetes Mellitus or
Cardiovascular Diseases receiving second-line treatment with intensive dose of Simvastatin
Atorvastatin and Atorvastatin-Ezetimibe combination in General Practice” In Proceeding of
ISPOR 20th Annual International meeting, Philadelphia, USA, May 16-20, 2015.

10. Tewthanom K. “Cost Effectiveness Analysis of Simvastatin Atorvastatin and Atorvastatin-
Ezetimibe combination among Patients with Diabetes Mellitus or Cardiovascular Diseases in
General Practice.” In Proceeding of ISPOR 20th Annual International meeting, Philadelphia, USA,
May 16-20, 2015.

11. Tewthanom K, Rattanakunooprakarn H. Factor affecting the assessment of the cost
effectiveness of statins in the primary prevention of coronary heart disease. Journal of TBPS
2014; 9,1: 38-56.

12. Duangmee K, Phetsai C, Khunthongphet U, Sengsoon N, Tewthanom K. Study of relationship
between trigger tools and adverse drug event at Somdet Phra Sangharaja the 19 th hospital,
Kanchanaburi. Conference: The 25th FAPA Congress 2014 in Malaysian Journal of Pharmacy, At
Kotakinabalu Malaysia, Malaysian Journal Volume: 1

13. Tewthanom K, Chaiwirattana N, Saelim W et al. Hypertensive medication discrepancies at the
time of hospital admission: the initiative problem’s survey process in community hospital
setting. J Pharm Biomed Sci. 2013; 26:406-09.

153